By: IPP Bureau
Last updated : August 04, 2026 5:42 pm
To support future CDMO opportunities, the company is expanding manufacturing capacity in phases, with plans to increase capacity to 1,200 KL by FY30
Morepen Laboratories Limited has reported its highest-ever quarterly revenue and earnings for the quarter ended June 30, 2026, driven by improved operating leverage, strong API and export performance, and the commercialisation of its Rs. 825 crore Contract Development and Manufacturing Organisation (CDMO) mandate.
The company reported revenue of Rs. 575.31 crore, up 34% year-on-year, while EBITDA jumped 207% to Rs. 87.72 crore. EBITDA margin expanded to 15.25% from 6.65% in the corresponding quarter last year. Profit after tax (PAT) increased 394% to Rs. 56.35 crore.
Export revenue more than doubled, growing 111%, while the API business registered 31% growth, with API exports rising 42%. The medical devices business also delivered 19% growth during the quarter.
A key highlight of the quarter was the commencement of full-scale commercial execution of the company's previously announced Rs. 825 crore CDMO mandate, with Rs. 58 crore worth of commercial supplies completed during Q1 FY27.
To support future CDMO opportunities, the company is expanding manufacturing capacity in phases, with plans to increase capacity to 1,200 KL by FY30.
Sushil Suri, Chairman & Managing Director, Morepen Laboratories Limited, said, “Q1 FY27 marks an important validation of Morepen’s transformation journey. The Company has delivered its highest-ever quarterly revenue, strong profitability improvement and meaningful operating leverage.”
“More importantly, our Rs. 825 Cr CDMO mandate has now entered full scale commercial execution, reinforcing our shift from a transaction-led API business to a more focused, manufacturing-led platform built around long-duration global partnerships,” added Suri.